Guggenheim analyst Vamil Divan raised the firm’s price target on AbbVie (ABBV) to $221 from $212 and keeps a Buy rating on the shares. The firm is updating its model following the company’s Q3 earnings results last week, stating that AbbVie reported “a solid quarter” with results beating on both sales and quarterly EPS.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ABBV:
- AbbVie price target raised to $180 from $175 at Deutsche Bank
- Roblox, Peloton upgraded: Wall Street’s top analyst calls
- AbbVie upgraded to Buy at Argus amid Skyrizi/Rinvoq sales growth, stable margins
- AbbVie upgraded to Buy from Hold at Argus
- Is AbbVie (NYSE:ABBV) Stock a Buy After Its Dividend Hike?